Effect of the Janus kinase inhibitor tofacitinib in the treatment of juvenile scleroderma: A single-center experience

Int J Rheum Dis. 2024 Aug;27(8):e15295. doi: 10.1111/1756-185X.15295.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Child
  • Female
  • Humans
  • Janus Kinase Inhibitors* / therapeutic use
  • Male
  • Piperidines* / therapeutic use
  • Pyrimidines* / adverse effects
  • Pyrimidines* / therapeutic use
  • Pyrroles / therapeutic use
  • Retrospective Studies
  • Scleroderma, Localized / diagnosis
  • Scleroderma, Localized / drug therapy
  • Scleroderma, Systemic
  • Time Factors
  • Treatment Outcome

Substances

  • tofacitinib
  • Pyrimidines
  • Piperidines
  • Janus Kinase Inhibitors
  • Pyrroles

Supplementary concepts

  • Juvenile-onset scleroderma